Literature DB >> 20842587

Tourette's Disorder.

Gholson J Lyon1, David Shprecher, Barbara Coffey, Roger Kurlan.   

Abstract

OPINION STATEMENT: Tourette's disorder (TD) is a common childhood-onset neuropsychiatric disorder characterized by chronic motor and vocal tics. TD frequently occurs with other neuropsychiatric disorders, such as attention deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD), and may contribute to reduced quality of life and disability. Currently available treatments to reduce tics are limited by variable clinical response and frequent adverse effects. They include alpha-2 agonists, antipsychotics (first and second generation), tetrabenazine, benzodiazepines, and habit reversal therapy. Some new and emerging (but unproven) treatments are also discussed, including topiramate and dopamine agonists. In addition, there is increasing interest in deep brain stimulation, but this is not yet ready for general use.

Entities:  

Year:  2010        PMID: 20842587     DOI: 10.1007/s11940-010-0073-x

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  49 in total

Review 1.  Habit reversal treatment of tic disorders: a methodological critique of the literature.

Authors:  James E Carr; Ivy M Chong
Journal:  Behav Modif       Date:  2005-11

2.  A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome.

Authors:  J Jankovic; J Jimenez-Shahed; L W Brown
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-09-01       Impact factor: 10.154

3.  Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder.

Authors:  F R Sallee; L Nesbitt; C Jackson; L Sine; G Sethuraman
Journal:  Am J Psychiatry       Date:  1997-08       Impact factor: 18.112

4.  Olanzapine in the treatment of aggression and tics in children with Tourette's syndrome--a pilot study.

Authors:  Robyn J Stephens; Chris Bassel; Paul Sandor
Journal:  J Child Adolesc Psychopharmacol       Date:  2004       Impact factor: 2.576

5.  Complementary and alternative medicine use in Gilles de la Tourette syndrome.

Authors:  Katie Kompoliti; Wenqin Fan; Sue Leurgans
Journal:  Mov Disord       Date:  2009-10-15       Impact factor: 10.338

6.  Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment.

Authors:  Xi-Ping Huang; Vincent Setola; Prem N Yadav; John A Allen; Sarah C Rogan; Bonnie J Hanson; Chetana Revankar; Matt Robers; Chris Doucette; Bryan L Roth
Journal:  Mol Pharmacol       Date:  2009-07-01       Impact factor: 4.436

7.  [Complex use of benzodiazepines, lithium salts and haloperidol in the treatment of obsessive movements and tics of different origin].

Authors:  S B Aksent'ev; N P Borisova; M V Levinskiĭ; G N Kryzhanovskiĭ
Journal:  Zh Nevropatol Psikhiatr Im S S Korsakova       Date:  1987

8.  Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome.

Authors:  James T McCracken; Robert Suddath; Susanna Chang; Sarika Thakur; John Piacentini
Journal:  J Child Adolesc Psychopharmacol       Date:  2008-10       Impact factor: 2.576

9.  Quetiapine treatment of children and adolescents with Tourette's disorder.

Authors:  Nahit Motavali Mukaddes; Osman Abali
Journal:  J Child Adolesc Psychopharmacol       Date:  2003       Impact factor: 2.576

10.  Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study.

Authors:  Gholson J Lyon; Stephanie Samar; Rahil Jummani; Scott Hirsch; Arie Spirgel; Rachel Goldman; Barbara J Coffey
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-12       Impact factor: 2.576

View more
  2 in total

1.  Catechol-O-Methyltransferase Gene Polymorphisms in Specific Obsessive-Compulsive Disorder Patients' Subgroups.

Authors:  Fernanda Brito Melo-Felippe; Juliana Braga de Salles Andrade; Isabele Gomes Giori; Tamiris Vieira-Fonseca; Leonardo Franklin Fontenelle; Fabiana Barzotti Kohlrausch
Journal:  J Mol Neurosci       Date:  2015-12-19       Impact factor: 3.444

2.  Topiramate and the vision: a systematic review.

Authors:  Mohammad-Ali Abtahi; Seyed-Hossein Abtahi; Farhad Fazel; Peyman Roomizadeh; Masoud Etemadifar; Keivan Jenab; Mojtaba Akbari
Journal:  Clin Ophthalmol       Date:  2012-01-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.